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HIV-1 infection is associated with changes in cognition and neuronal function, known as 
HIV-associated neurocognitive disorder (HAND), with the most severe form resulting in 
dementia. Astrocytes in the frontal cortex have a critical role in neuropathogenesis induced by 
HIV-1 as they undergo “astrocytosis” that is commonly found in HAND subjects. Astrocytes are 
a type of glial cells located in the central nervous system and are targets for HIV-1 infection, 
though it is defective in producing replication competent viruses. However, the infected 
astrocytes are capable of producing viral proteins and are reactivated. These star-shaped cells 
serve many functions, such as providing structural and metabolic support to nearby neurons, and 
have a central role in the maintenance of the neuronal synapse and the blood brain barrier. 
Astrocytes undergo structural and functional transformations in the occurrence of CNS infection, 
but it is unclear whether this plays a role in HIV-1 pathogenesis. Host cellular factors including 
microRNAs have been suggested to regulate the balance between neuroprotective and neurotoxic 
factors in astrocytes.  While combination antiretroviral therapy (cART) can be used to treat viral 
replication, these drugs do not penetrate the central nervous system, and therefore treatment of 
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infection within the brain is limited. Thus, identifying new therapeutics is important to reduce the 
burden of HAND, which has great public health significance.  
We have previously identified candidate miRNA that are known to have potential 
neuroprotective effects. In my project, I evaluated whether these miRNA have a role in 




TABLE OF CONTENTS 
PREFACE .................................................................................................................................... XI 
1.0 INTRODUCTION................................................................................................................ 1 
1.1 HIV-1 PATHOLOGY ................................................................................................. 2 
1.2 HIV-1 PATHOGENESIS AND THE CENTRAL NERVOUS SYSTEM ............. 6 
1.3 HIV-1 PATHOGENESIS AND HIV-ASSOCIATED NEUROCOGNITIVE 
DISORDERS (HAND) ......................................................................................................... 7 
1.4 HIV-1 AND THE BLOOD BRIAN BARRIER ........................................................ 8 
1.5 ASTROCYTES ........................................................................................................... 9 
1.6 ASTROCYTES AND HIV-1 PATHOGENESIS ................................................... 10 
1.7 ASTROCYTOSIS ..................................................................................................... 10 
1.8 MICRORNA .............................................................................................................. 14 
1.9 MICRORNA AND HIV-1 INFECTION ................................................................ 15 
2.0 AIMS OF THE PROJECT ............................................................................................... 17 
3.0 MATERIALS AND METHODS ...................................................................................... 18 
3.1 293T CELLS .............................................................................................................. 18 
3.2 TZM-BL CELLS ....................................................................................................... 18 
3.3 ASTROCYTE CELLS.............................................................................................. 19 
3.4 CONSTRUCTION OF MIRNA EXPRESSING ASTROCYTE CELL LINES . 19 
 vii 
3.5 VERIFICATION OF MIRNA TRANSDUCTION IN ASTROCYTES BY 
FLOW CYTOMETRY ...................................................................................................... 20 
3.6 TOTAL RNA EXTRACTION ................................................................................. 20 
3.7 VIRUS PRODUCTION ............................................................................................ 21 
3.8 QUANTIFYING VIRUS TITER ............................................................................. 22 
3.9 INFECTION OF NORMAL HUMAN ASTROCYTES ....................................... 23 
3.10 INFECTION OF MIRNA TRANSDUCED ASTROCYTES ............................... 23 
3.11 INFECTION OF TZM-BL CELLS WITH SUPERNATANT FROM 
INFECTED ASTROCYTES ............................................................................................. 24 
3.12 BETA GALACTOSIDASE ENZYME ASSAY TO TEST THE INFECTIVITY 
OF VIRUS PRODUCED BY THE INFECTED MIRNA EXPRESSING 
ASTROCYTES ................................................................................................................... 24 
4.0 RESULTS ........................................................................................................................... 25 
4.1 GENERATE ASTROCYTE CELLS EXPRESSING CANDIDATE MIRNA ... 25 
4.1.1 Verification of transduction via fluorescent microscopy ........................... 25 
4.1.2 Verification of Transduction via Flow Cytometry ..................................... 26 
4.1.3 Total RNA Extraction ................................................................................... 27 
4.2 INFECTION OF NORMAL AND MIRNA EXPRESSING ASTROCYTES ..... 27 
4.2.1 293T Infectivity Assay ................................................................................... 27 
4.2.2 Verification of Infection of Normal Human Astrocytes via Fluorescent 
Microscope .................................................................................................................. 28 
4.2.3 Verification of Infection of miRNA Expressing Astrocytes via TZM-bl 
Infectivity Assay ......................................................................................................... 29 
 viii 
5.0 CONCLUSION .................................................................................................................. 32 
6.0 DISCUSSION ..................................................................................................................... 34 
6.1.1 Limitations ..................................................................................................... 35 
6.1.2 Future Directions ........................................................................................... 36 
BIBLIOGRAPHY ....................................................................................................................... 38 
 ix 
LIST OF TABLES 
Table 1. Candidate miRNA Selected for Study and their Predicted Biological Effect ................ 16 
Table 2. Viruses of Interest ........................................................................................................... 22 
Table 3. RNA Extraction Results.................................................................................................. 27 
Table 4. Estimation of virus titer using TZM-bl cells .................................................................. 28 
Table 5. Transfection of Normal Human Astrocytes: Evidence of Green Fluorescence as 
Observed under Microscope ......................................................................................................... 29 
 x 
LIST OF FIGURES 
Figure 1. The HIV-1 genome .......................................................................................................... 4 
Figure 2. Fluorescent Microscope Images of miRNA transduced astrocytes ............................... 25 
Figure 3. Flow Cytometry Results of miRNA Expressing Astrocytes. ........................................ 26 
Figure 4. β-Gal Assay to Quantify Virus Infectivity in TZM-bl cells .......................................... 31 
 xi 
PREFACE 
I would like to thank Dr. Jay Venkatachari and Ms. Roberta Reis for their guidance, patience, 
and advice while teaching me the techniques and procedures used in this project. I would also 





1.0  INTRODUCTION 
Human Immunodeficiency Virus-1 (HIV-1) is a global public health issue, having claimed over 
35 million lives to date. Approximately 36.7 million individuals have been infected with HIV-1, 
as of 2016, with 1.8 million new cases of the virus within 2016 alone. HIV-1 is a virus that 
targets the immune system and weakens its ability to fight off infections. HIV-1 is spread 
through sexual behaviors, contact with mucous membranes, and through contact with 
contaminated needles and syringes [1]. The symptoms of HIV-1 infection can vary depending on 
the stage of infection. In fact, many individuals are unaware of their status until later stages, as 
they may not experience any symptoms within the initial weeks of infection. HIV-1 infection is 
diagnosed through rapid diagnostic tests (RDTs), which measure the levels of HIV-1 antibodies 
within the blood [1].  
There are three stages of HIV-1 infection, with the most advanced and serious stage 
resulting in Acquired Immunodeficiency Syndrome (AIDS). The first stage of infection is known 
as acute HIV-1 infection, which develops two to four weeks after infection. Symptoms of the 
acute stage include fever, headache, and rash. The risk of HIV-1 transmission is very high at this 
stage of infection, due to high levels of virus within the blood.  The second stage of HIV-1 
infection is known as chronic infection, where HIV-1 continues to replicate within the body, but 
at lower levels. Without treatment, chronic infection can lead to AIDS anywhere from 2 to 15 
years after initial infection. Finally, the third stage of infection, AIDS, is the most severe form. 
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At this stage, HIV-1 has greatly damaged the body’s immune system, making the individual 
susceptible to other infections and cancers [2].  
HIV-1 in an interesting disease because differences in awareness and treatment practices 
around the world influence the distribution of HIV-1 cases globally. While HIV-1 does not 
discriminate against who can be infected with the virus, there are some populations who are at 
higher risk of being exposed to HIV-1. Those at higher risk of infection include men who have 
sex with men, those who inject drugs, sex workers, and transgender individuals [1].  
There is currently no cure for HIV-1. However, with new technology and advanced 
research, effective antiretroviral drugs (ART) can help control the replication of the virus and 
prevent its transmission. ARTs have been successful in reducing the mortality rate of HIV-1 as 
well as in prolonging the lifespan of individuals infected with the disease [3]. Furthermore, 
additional treatment such as healthy lifestyle, nutritious diet, and reducing stress can help to 
alleviate some of the symptoms associated with HIV-1 infection. While there have been 
significant strides in the understanding and treatment of HIV-1 and its pathogenesis, there is still 
a great deal of information left to learn about the biology of the virus in order to create a cure for 
the disease. 
1.1 HIV-1 PATHOLOGY 
The Human Immunodeficiency Virus is a virus that belongs to the Lentivirus genus of the 
Retroviridae family. The virus has two copies of a positive single strand RNA genome that is 
integrated into the DNA of the host cell, through a seven-step mechanism. HIV-1 infects CD4+ 
T cells and macrophages through the interaction of surface viral envelope proteins with the CD4 
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receptor and chemokine co-receptor (CXCR4 or CCR5) on the host cell. These receptors allow 
for virus entry into the cell by facilitating fusion of the viral and cell membrane [4]. CXCR4 
receptors have been shown to facilitate HIV-1 entry into lymphocytes and CCR5 receptors into 
monocytes, macrophages, and microglia along with the CD4 receptor. For this reason, HIV-1 
viral strains that utilize the CXCR4 receptor are known as X4 viruses and those that use the 
CCR5 receptor are known as R5 viruses [5].  
After the virus enters the cell, HIV-1 releases viral reverse transcriptase enzyme, which 
converts the viral RNA to viral DNA. The viral DNA is then transported into the cell nucleus via 
an integrase enzyme, which facilitates the integration of the viral DNA into the host cell genome. 
Once the HIV-1 genome becomes part of the host cell DNA, the virus begins replicating using 
the host cell machinery. This replication process releases long chains of HIV-1 proteins, which 
are the building blocks for mature HIV-1 protein [4].  
These HIV-1 proteins then move to the surface of the host cell where they assemble into 
immature HIV-1 virions. In the last step of HIV-1 replication, the immature HIV-1 virions “bud 
off” from the host cell and the genome releases a protease enzyme, which breaks up the HIV-1 
immature virions to form infectious HIV-1 virions [4].  
The HIV-1 genome has several structural and regulatory features that help to make it a 
successful retrovirus within an infected cell. The HIV-1 virion is approximately 120 nm in 
diameter and contains 2 RNA strands that are each 9 kb long. The genome contains nine genes, 
which contribute to creating 15 different protein products, which are necessary for the virus to 
establish an infection within a host cell (Figure 1). These proteins play varying roles within the 




Figure 1. The HIV-1 genome 
 
The HIV-1 provirus has two repeated sequences on either end of the genome, which are 
known as Long Terminal Repeats (LTRs). The LTR region of the genome contains several 
binding sites where host transcription factors and viral proteins interact and initiate viral 
transcription [7]. The genes located within the middle of the genome are responsible for 
encoding three main classes of proteins: structural, regulatory, and accessory proteins.  
The first structural protein on the HIV-1 genome is known as Gag. Gag is a polyprotein 
that recruits two copies of the viral RNA and other cellular proteins to facilitate the budding of 
the viral particle from the infected cell. After the infectious particle has budded off from the 
infected host cell, the Gag protein is broken down into four smaller proteins, MA, CA, NC, and 
p6, each of which serve various functions in helping the virus establish infection within the host 
cell [8].  
The second structural protein, Pol, encodes four different viral enzymes: Protease (Pro), 
integrase (IN), RNase H, and reverse transcriptase (RT). The protease enzyme is responsible for 
preparing the virion for entry into the host cell [9]. Once the virus enters the cell, the reverse 
transcriptase enzyme makes a cDNA copy of the viral RNA genome. The RNase H then removes 
the RNA template strand from the DNA copy and allows for the synthesis of a complementary 
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DNA strand to be made. Finally, the integrase enzyme functions to insert the viral HIV-1 DNA 
into the DNA of the host cell [8].  
Finally, the last structural protein that is encoded by the HIV-1 genome is known as Env. 
Env is a structural protein that is required to establish infection within the host cell [6]. Env is 
cleaved into two proteins, gp41 and gp120. Gp41 serves to facilitate the fusion of the viral and 
cellular membranes, in order to allow the virus to deliver the viral proteins into the cytoplasm of 
the host cell. Gp120 also mediates viral entry into the host cell, through interactions with the 
virus receptor CD4. Certain sequences on the gp120 protein interact with the co-receptors 
CXCR4 or CCR5 and these can affect the infectivity of the virus within a host cell [8].  
In addition to structural proteins, the HIV-1 genome contains two regulatory proteins, Tat 
and Rev, which are responsible for mediating the transcription of the viral RNA. Tat serves 
several functions, including influencing the splicing of the HIV-1 RNA, modulating the reverse 
transcription of the RNA genome, and finally, mediating the expression of cellular genes [10]. 
The second regulatory protein, Rev, is an RNA binding protein and is a necessary for HIV-1 to 
replicate. Rev facilitates the transport of viral RNAs from the nucleus of the host cell to the 
cytoplasm and can regulate the levels of splicing that occur with this newly made RNA [8]. 
Furthermore, the HIV-1 genome contains four accessory proteins, all of which serve 
various functions within the HIV-1 replication process, particularly to evade the host cell’s 
immune function. The Nef protein, or negative factor protein, is responsible for inducing disease 
once infection has been established within the host cell. Nef serves to degrade CD4 receptors on 
the cell surface as well as down-regulate the level of viral replication once the infection has been 
established, in order to avoid detection by the host cell [11].  
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Another accessory protein of the HIV-1 genome is viral protein R (Vpr). Vpr, with the 
aid of some other proteins, facilitates virus entry into the nucleus of the host cell, so that the 
genome may be incorporated into that of the target cell. In particular, Vpr allows HIV-1 to infect 
non-dividing cells, which further increases the virus’ persistence within the host cell [12].  
In a similar way, the viral protein U (Vpu) also plays a role in helping the virus evade the 
host immune response. Vpu acts in two specific ways. The first is by degrading the CD4 receptor 
on the cellular surface, in order to allow for virion assembly within the host cell. Secondly, the 
Vpu protein increases the release of newly formed HIV-1 particles from the surface of the host 
cell [13].  
Finally, the last accessory protein that is present within the HIV-1 genome is the virion 
infectivity factor (Vif) protein. Vif is the protein that aids in HIV-1 replication within 
lymphocytes and macrophages, cells that are typically non-permissive. The Vif protein has also 
been shown to have a role in the assembly of viral proteins. In all, the four accessory proteins of 
the HIV-1 genome help to establish persistent infection within the target cell and are primarily 
responsible for evading the host cell immune response [14].  
1.2 HIV-1 PATHOGENESIS AND THE CENTRAL NERVOUS SYSTEM 
HIV-1 invades the central nervous system (CNS) soon after initial infection via infected 
macrophages, where it can exist for several years after initial infection. Neurons are not directly 
infected by HIV-1. However, neurons can be indirectly injured from the presence of viral 
proteins, such as gp120 and tat, as well as the neurotoxins produced from surrounding infected 
cells [15].  
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 While ART is used to treat HIV-1 infection and viral replication specifically, these drugs 
do not penetrate the blood-brain-barrier (BBB) of the CNS, and therefore treatment of infection 
within the brain is limited. HAND is becoming more prevalent as individuals infected with HIV-
1 are living longer [16]. 
HIV-1 replication within the CNS is regulated by a number of factors, indicating that the 
surrounding environment influences the ability of the virus to replicate within the brain. When 
the virus is able to replicate highly actively, the process is known as “productive” infection, 
whereas a low/undetectable virus production is termed “restricted”. Productive infection 
contributes to the rapid transmission of the virus within host cells, whereas cells that are able to 
restrict infection are able to survive HIV-1 infection. These cells become virus reservoirs, which 
are able to produce viral genomes in a stable state. The virus in these reservoirs is able to become 
re-activated with changes to the surrounding environment, causing infection symptoms much 
later after initial infection. Both types of infection can occur within the CNS [15].  
1.3 HIV-1 PATHOGENESIS AND HIV-ASSOCIATED NEUROCOGNITIVE 
DISORDERS (HAND) 
With modern day advances in treatment and diagnosis of HIV-1 infection, individuals diagnosed 
with HIV-1 are living longer than those in the past. Many of those who are diagnosed with 
modern methods are living complete lifespans and experience less complications than before [1].  
Infection within the CNS can lead to neurological problems, such as motor and cognition 
impairments and behavior changes. The infection of the CNS is associated with changes in 
cognition and neuronal function, known as HIV- associated neurocognitive disorders (HAND). 
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The least severe form of HAND is called Asymptomatic Neurocognitive Impairment (ANI). 
Symptoms of ANI include minor neurocognitive impairments, however these have no impact on 
daily functional performance. A milder form of impairment, known as Mild Neurocognitive 
Disorder (MND), is associated with neurocognitive impairment that affects activities of daily 
living. Finally, the most severe form of HAND is known as HIV- associated dementia (HAD). 
HAD symptoms include impairments in several cognitive domains and have a large impact on 
daily functioning [17].  
 Even though treatment with ARTs has reduced the number of HAD cases, neurological 
problems still persist in those individuals who have prolonged infection. As more HIV-1 positive 
individuals continue to live longer on ART, the prevalence of HAND has increased. Current 
treatments do not target virus replication within the brain. Therefore, studying the pathogenesis 
of HIV-1 within the brain in relation to the development of HAND is an important issue [15].  
1.4 HIV-1 AND THE BLOOD BRIAN BARRIER 
The blood brain barrier is a layer of endothelial cells that separates toxic substances in the 
circulating blood and prevents them from entering the brain. The BBB also supplies the brain 
with essential nutrients. The cells that comprise the BBB are surrounded by astrocyte processes, 
which serve to provide structural and functional support to the endothelial layer [15].  
HIV-1 is unique in that the virus is able to overcome this barrier and enter the brain. 
There are many proposed mechanisms for this; the most commonly accepted one being the 
“Trojan horse” hypothesis. This hypothesis suggests that HIV-1 enters the brain through infected 
monocytes, which cross the BBB. These monocytes serve as carriers of HIV-1 to the brain and 
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upon entry, release viral proteins that disturb the astrocyte’s ability to regulate the permeability 
of the BBB [15]. It is for this reason that astrocytes are an area of interest for further 
investigation in regards to HIV-1 pathogenesis within the central nervous system.  
When HIV-1 invades the BBB, the infection causes a pro-inflammatory response with the 
release of numerous cytokines, including TNF-α and IL-1β. Furthermore, endothelial cells that 
are activated by the virus upregulate the expression of adhesion molecules, which facilitates the 
leakage of more infected monocytes into the brain [15].  
1.5 ASTROCYTES  
Astrocytes are star-shaped glial cells that are the most abundant cell type within the CNS. They 
serve a variety of functions including providing structural support to nearby neurons and 
maintaining the neuronal synapse and the blood brain barrier. Astrocytes also have a role in 
regulating brain homeostasis, synaptic transmission, and plasticity. Furthermore, astrocytes can 
be targeted by the immune system in the event of infection and neuronal injury [18].   
 Astrocytes actively respond to pathological stress by becoming activated, not only at the 
site of the injury, but also in the surrounding environment. Several studies have shown that 
cytokines, growth factors, and cell surface molecules are up regulated within these activated 
astrocytes. Previous literature has also provided evidence for the role of astrocytes as mediators 
in the event of HIV-1 neuronal injury. However, the pathogenesis of this process and the specific 
mechanism by which astrocytes act is still a topic of investigation [18].  
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1.6 ASTROCYTES AND HIV-1 PATHOGENESIS  
Astrocytes are target cells for HIV-1 and upon infection can be activated, a process known as 
astrocytosis. Though astrocytes are defective in producing replication competent virus, the 
infected astrocytes are capable of producing viral proteins. These cells undergo structural and 
functional transformations in the occurrence of CNS infection, but it is unclear what role these 
cells play in HIV-1 pathogenesis [15]. Host cellular factors including microRNAs have been 
suggested to regulate the balance between neuroprotective and neurotoxic factors in astrocytes 
[19].  
1.7 ASTROCYTOSIS  
Neuronal injury and stress can cause astrocyte activation, or astrocytosis, which is when there is 
an irregular increase in the size and number of astrocyte cells within the CNS. Astrocyte 
activation is characterized by hypertrophy of neurons, cell proliferation, alteration in molecular 
expression, and an upregulation of glial fibrillary acidic protein (GFAP) expression. 
Furthermore, HIV-1 infection can activate astrocytes and cause them to produce various 
chemotactic factors [18]. These changes can alter astrocyte activity and affect the surrounding 
neuronal structures. In it unclear whether these structural and functional transformations play a 
role within astrocytes in HIV-1 pathogenesis.  
Astrocytes, specifically activated astrocytes, are identified by the expression of GFAP, 
which is an intermediate protein located in the main processes and the body of astrocytes. This 
protein plays a role in cell communication, cell migration, mitosis, and cytoskeletal changes. The 
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upregulation of GFAP, an astrocyte specific protein, during activation is caused by neurological 
injury, and is a hallmark feature of neurological diseases, including Alzheimer’s disease, 
Parkinson’s disease, and HAND [20].  
In previous studies, HIV-1 infected individuals have shown symptoms of astrocytosis 
triggered not only by virus infection, but also by the presence of viral proteins. For this reason, 
astrocytosis is considered to be a hallmark feature of HIV-1 infected brain cells. This leads to the 
belief that astrocyte dysfunction during HIV-1 infection of the CNS play an important role in 
HIV-associated neuropathogenesis and the development of HAND [21].  
Furthermore, activated astrocytes have been shown to release neurotoxic factors such as 
excitatory amino acids (ex. Glutamate) and TNF-α. Additionally, gp-120 has been shown to up-
regulate Nrf2, a transcription factor that is involved in antioxidant defense mechanism [22]. Gp-
120 also induces the expression of several cytokines, such as IL-6, within astrocyte cells, through 
a nuclear-kappa β-dependent (NF-k β) mechanism. It is hypothesized, therefore, that the 
neuroinflammation caused by HIV-1 infection is mediated by the NF-k β pathway, however the 
mechanism of this is still under further research [23].  
Another factor that plays a role in astrocytosis and the communication signals between 
infected astrocytes are gap junctions. Gap junctions are the intracellular space, which allow the 
cells to communicate with each other, through the transfer of ions, second-messenger molecules, 
and peptides, between the cytoplasm of neighboring cells [24]. Astrocytes utilize gap junctions 
to communicate with each other, but also to communicate with neurons and other glial cells [25]. 
Astrocyte gap junctions specifically regulate ATP release and glutamate homeostasis within the 
brain. These gap junctions also play a role in filtering out extra K+ ions that become present 
within the extracellular space after neuronal activity [26]. It is hypothesized that HIV-1 infected 
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astrocytes utilize gap junctions to spread toxic signals to uninfected astrocytes. In fact, gap 
junctions are thought to amplify the toxic signals from infected to uninfected cells, leading to 
severe HIV-1 associated CNS dysfunction. Evidence for this has been shown with Tat-induced 
dysfunction of the BBB, which causes an altered expression of specific tight junction proteins 
[27].  
Another important role of astrocytes include regulating the amount of K+ ions that are 
present within the extracellular space, which affects the ability of neurons to survive and 
function. During normal neuron function, K+ ions move from the cytoplasm of the cell to the 
extracellular space. An uncorrected increase in these ions within the extracellular environment 
would cause the depolarization of the neuronal membrane, which would interrupt synaptic 
transmission. Astrocytes function by clearing the extracellular K+ ions through a combination of 
mechanisms, including active uptake, co-transport, and K+ transport channels. It is hypothesized 
that the function of these K+ channels are interrupted or disturbed during HIV-1 infection, which 
can potentiate HAND pathogenesis, however the mechanism by which this occurs is still under 
investigation [28].  
In addition to these various functions, astrocytes play another vital role in CNS 
physiology, by regulating the levels of glutamate within the extracellular space. Glutamate is an 
excitatory neurotransmitter that is responsible for proper neuron functioning and signaling. 
However, excess amounts of glutamate present in the synaptic space can lead to neuronal death 
through excitotoxicity. Astrocytes are the main cell that is responsible for the uptake of excess 
glutamate, as their membranes contain the necessary transporters [29]. In fact, 90% of glutamate 
uptake within the brain occurs via astrocytic glutamate transporters [30]. It is believed that 
excitotoxicity caused by excess glutamate can lead to various neurological disorders such as 
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Alzheimer’s disease. In HIV-1 infected individuals, this excitotoxicity can lead to HAND [18]. 
The mechanism of this is thought to occur via HIV-1 envelope proteins, gp-120 and gp41, which 
block glutamate transporters within the astrocyte membrane, which impairs the ability of these 
cells to uptake and clear the glutamate within the extracellular space [18].  
Furthermore, the calcium ion (Ca2+) plays a vital role within astrocyte function, by acting 
as a second messenger. Ca2+ in astrocytes transfers signals between astrocytes and neurons, to 
further cell signaling. The levels of Ca2+ located within the intracellular space greatly affect how 
well the astrocyte is able to transduce a signal as well as the plasticity of the cells within the 
CNS. An excess amount of Ca2+ within the intracellular space can result in excitability. In 
astrocytes specifically, Ca2+ is responsible for the release of neurotransmitters such as glutamate. 
In the case of HIV-1 infection, the viral protein Tat can affect the levels of Ca2+ within the 
intracellular space and affect these functions of the astrocyte, which can lead to neuronal 
excitotoxicity. Ca2+ ion is yet another method by which HIV-1 infection induces HIV-1 
neurotoxicity and can lead to the pathogenesis of HAND [31].  
As mentioned earlier, several glutamate transporters and potassium channels are located 
within the astrocyte processes, which are constantly in contact with the BBB. In the case of HIV-
1 infection, the viral proteins alter the function of these channels within astrocytes, which 
compromises the integrity of the BBB. Additionally, Tat and gp120 can elevate intracellular 
levels of Ca2+ , which can cause the release of several metabolic factors that regulate the blood 
flow and dilation of the surrounding capillaries. These proteins also alter the expression of gap 
junctions in relation to the BBB, which likely increases the permeability of the BBB to harmful 
toxins. It is believed that it is via this mechanism that HIV-1 infection and further progress 
within the brain, once already established by the monocytes [30].  
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Finally, astrocytes frequently communicate with neurons and vice versa, which 
contributes to the development of the CNS and the repair and aging process within the brain. It is 
therefore believed that the impairment of astrocytes via HIV-1 infection can contribute to 
neurological diseases, especially HAND [18]. For example, Tat released from infected astrocytes 
has been shown to cause cell death and mitochondrial dysfunction within surround neurons. 
Additionally, the supernatant of infected astrocytes contains factors that are neurotoxic to 
neurons. Furthermore, astrocytes that have been infected with virus can greatly affect synaptic 
transmission. HIV-1 Tat and gp120 activate astrocytes to release cytokines, such as TNF-α, IL-1, 
and IL-1β, which are known to have proinflammatory affects, and which can lead to neuronal 
injury within the brain [33].  
In conclusion, astrocytes play a critical role in the proper functioning of the brain. These 
cells regulate brain homeostasis, synaptic transmission, and support the metabolic functions of 
the surrounds cells. Since astrocytes have so many roles, as stated above, they are of great 
research interest in order to elucidate the pathogenesis of HIV-1 infection within the brain. 
Astrocytes could potentially be a point of therapeutic intervention, especially within the realm of 
HIV-1 pathogenesis and HAND. This serves as the basis for the project of this thesis and why 
astrocytes were chosen as the cell of interest for this project.  
1.8 MICRORNA  
MicroRNAs are non coding RNAs generated by host cells that can be targeted as a therapeutic. 
MicroRNAs are small nucleotide regulatory, noncoding RNA molecules that are encoded by the 
host genome and are not translated into proteins [19]. MicroRNAs regulate gene expression by 
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binding to the 3’ untranslated region of target messenger RNAs (mRNAs) through 
complementary base pairing. This binding leads to reduced protein expression, as the miRNA 
represses the translation of the mRNA or degrades the mRNA so that it is unable to be translated. 
These miRNA play a central role in cellular processes such as cell proliferation, differentiation, 
and death [19]. Some recent studies have also shown high levels of miRNA expression within 
the CNS as well [34].  
1.9 MICRORNA AND HIV-1 INFECTION  
The virus overcomes several host cellular factors in order to establish active infection within the 
host cell, which are known as “HIV dependency factors” (HDF’s). These dependency factors can 
be targeted as potential therapeutics to treat HIV-1 infection. The role of miRNA in the 
pathogenesis of HIV-1 infection is currently an area of interest. In previous studies, some 
miRNAs have been shown to bind to viral RNA and inhibit the replication of the viral genome 
[35]. In another hypothesis, some miRNA are believed to affect HDFs in order to reduce HIV-1 
virus replication [35]. For this reason, the interaction between miRNA and virus infection is of 
great interest, in an effort to create therapeutics to target HIV-1 within the CNS [19].  
The Ayyavoo lab has shown that specific miRNAs have neuroprotective roles within the 
CNS in case of HIV-1 infection (Unpublished lab data). These neuroprotective miRNAs are 
enriched in HAND resistant subjects, which indicates that these miRNAs may play a role in 
preventing the onset of HAND in cases of chronic infection. Using information from the Multi 
Center AIDS Cohort Study, the Ayyavoo lab identified 12 HIV-1 positive patients who did not 
develop HAND for over 15 years after initial infection (HAND resistant group). After comparing 
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the transcriptomes of these patients with those of HIV-1 negative patients and HIV-1 positive 
patients with mild neurocognitive disorder (MND) and HIV-1 associated dementia (HAD), 
unique changes in the transcriptome of the HAND resistant group were found. The analysis 
found 21 miRNA sequences that target 98 different mRNAs in the HAND resistant group. This 
is in contrast to the MND and HAD groups, where only 4 miRNAs targeting 10 mRNA and 5 
miRNAs targeting 30 mRNAs were found, respectively. By evaluating these miRNA and their 
gene targets with their biological function, the lab determined that the miRNAs that were 
upregulated in the HAND resistant group are associated with the gene targets of several 
cytokines, that have a neuroinflammatory role during neuronal injury (Table 1). This suggests 
that these miRNAs, if upregulated in HIV-1 positive individuals who do not develop HAND, can 
neutralize the effects of these cytokines in HAND pathogenesis. This study and the results 
obtained from the analysis serve as the rationale behind the project that is the focus of this thesis. 
 
Table 1. Candidate miRNA Selected for Study and their Predicted Biological Effect 
miRNA Target mRNAs Target Cell Biological Effect  
Scramble   Astrocytes  Represses inflammatory 
response in presence of 
neuronal injury.  
let-7a (miR-141) IL6R, CCL2 Astrocytes  Regulates inflammatory 
response by targeting 
CXCL12.  
miR-17-5p (miR-20a and 
miR-106b)  
IL8, STAT3 Astrocytes  Inhibits HIV-1 infection 
by targeting Tat mRNA 
and reducing its 
translation.  
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2.0  AIMS OF THE PROJECT  
Listed below are the specific aims to evaluate the role of microRNAs as therapeutics to block 
virus replication in astrocytes.  
Aim 1: To generate and characterize the astrocyte cell lines expressing candidate 
miRNAs along with appropriate control.  
A. Transduce normal human astrocytes with candidate miRNA using an miRNA 
expression vector.  
B. Confirm transduction via microscopy, flow cytometry and RNA Polymerase Chain 
Reaction (qRT-PCR).  
Aim 2: To determine whether the overexpression of these candidate miRNA block 
virus replication.  
A. Generate 6 different HIV-1 viruses through transfection of 293T cells with viral 
plasmids.  
B. Infect normal human astrocytes and miRNA expressing astrocytes with each virus 
type and confirm successful transfection via fluorescent microscope.  
C. Infect TZM-bl cells with the supernatant from the infected astrocytes to determine 
the infectivity of the virus produced.  
D. Quantify levels of infection using TZM-bl cells based β-Galactosidase assay.  
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3.0  MATERIALS AND METHODS 
3.1 293T CELLS  
293T cells were used to initially generate the viruses used in this study. 293T cells are human 
embryonic kidney cells that are commonly used for virus production for their ability to become 
easily transfected with viral plasmids. These cells grow rapidly, allowing for the production of a 
large viral titer for each virus created. The 293T cells were maintained in T-75 flasks, in 10 mL 
of D10 media.  
3.2 TZM-BL CELLS  
TZM-bl cells were used in this study to test the titer of the virus created from the 293T cells as 
well as the infectivity of the viral proteins produced from infected astrocytes. TZM-bl cells are 
derived from a HeLa cell line that was engineered to express the CD4, CCR5, and CXCR4 
receptors. These cells are therefore able to successfully be infected with HIV-1, and can be used 
to test the viral titer of a given virus. The TZM-bl cells were maintained in T-75 flasks, in 10 mL 
of D10 media.   
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3.3 ASTROCYTE CELLS  
Normal human astrocytes used in this study were obtained from Gibco. These cells are human 
brain progenitor-derived astrocytes, which have been tested for the astrocyte-specific marker 
called glial fibrillary acid protein (GFAP). These cells were maintained in an astrocyte- specific 
media (obtained from Gibco), which was stored in -20°C. The astrocyte media consisted of 
DMEM, supplemented with N-2 and FBS (necessary growth factors). The astrocyte cells were 
maintained in T-75 flasks, in 10 mL of astrocyte-specific media.  
3.4 CONSTRUCTION OF MIRNA EXPRESSING ASTROCYTE CELL LINES  
This study’s first aim was to construct astrocyte cell lines expressing candidate miRNA. In order 
to accomplish this, normal human astrocytes were transduced with candidate miRNA using a 
lentivirus expression vector. These miRNAs were previously identified as neuroprotective by 
profiling and co-expression analysis.  
After transduction, puromycin resistant cells were selected for. Finally, microscopy, flow 
cytometry and RNA PCR were used to confirm the transduction of the candidate miRNA.  
Four candidate miRNA were selected for this study:  
1. Scramble: Control for miRNA constructs.   
2. miR-let-7a: tumor suppressor miRNA that promotes anti-inflammatory factors [36].   
3. miR- 141: regulates inflammatory response by targeting CXCL12 [37].  
4. miR- 20a: inhibits HIV-1 infection by targeting Tat mRNA and reducing its 
translation[38].  
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3.5 VERIFICATION OF MIRNA TRANSDUCTION IN ASTROCYTES BY FLOW 
CYTOMETRY  
Forty-eight hours post transduction, the miRNA transduced astrocytes were washed with PBS 
and fixed in 3.7% formaldehyde at room temperature for one hour. The cells were then washed 
and resuspended in 200μL of FACS buffer. Analysis of flow cytometry was performed on the 
FACSAriaTM cell analyzer using the FACSDiva® software. EGFP expression was used to 
analyze the cells.  
3.6 TOTAL RNA EXTRACTION  
Total RNA extraction was performed using the mirVanaTM miRNA Isolation Kit. MicroRNA 
expressing astrocytes cell cultures were first washed with PBS and trypsinized to detach them 
from the T75 flask. After a ten-minute incubation period, the trypsin was deactivated with D10 
media. One million cells were then spun down at 1000 rpm for five minutes to obtain the cell 
pellet. The cells were washed with PBS and lysed in 500 μL of Lysis/Binding Solution. Next, 50 
μL of miRNA Homogenate Additive was added to the lysate and mixed for 30 seconds by 
vortex. The mixture was then left on ice for ten minutes. After ten minutes, 500 μL of Acid-
Phenol: Chloroform was added to the solution and vortexed for approximately one minute. The 
cell solution was then centrifuged at 10,000rpm for 5 minutes in order to separate the organic 
and the aqueous layers. The aqueous layer (500 μL) was carefully removed from the cell solution 
and transferred to eppendorf tubes.  Next the Elution Solution was heated to 95°C. 625 μL of 
100% ethanol was then added to the aqueous phase, and this mixture was then passed through 
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the RNA binding membrane. Next, 700 μL of miRNA Wash Solution 1 was added to the filter 
cartridge centrifuged for 15 seconds to allow for the solution to pass through the filter. The flow-
through was discarded. 500 μL of miRNA Wash Solution was then added to the filter and 
centrifuged similarly as in previous steps. This step was repeated a second time with another 500 
μL aliquot of the Wash Solution 2/3. After three washes, the flow through was discarded and the 
filter cartridge was placed in a new collection tube and centrifuged for one minute to remove any 
residual fluid. Next, the filter cartridge was again placed in a new collection tube and 100 μL of 
the heated Elution Solution (95°C) was added to the filter. The collection tube was then 
centrifuged again for 30 seconds and the eluate was collected. Finally, the concentration of the 
RNA was measured by spectrophotometer. Due to the low concentration of the RNA, it was not 
converted to cDNA and real time PCR was not performed.  
3.7 VIRUS PRODUCTION 
In order to produce sufficient virus for this study, 1.0 X 106 293T cells were plated in 10 mL of 
D10 media on a 10 cm2 tissue culture plate. Cells were grown for 24 hours to achieve 80% 
confluency before performing the transfection. One hour before performing the transfection, the 
existing was removed and replaced with 8 mL of fresh media per plate. The transfection was 
then done using 5 μg of viral DNA, for each of the 6 viruses of interest, in 15 μL of Polyjet 
transfection reagent, diluted in 250 μL of plain DMEM. This solution was then added drop-wise 
to each plate of 293 T cells (2 plates/virus). The transfection media was then removed after 
twenty-four hours, and replaced with 8 mL of fresh D10 media. The plates were the incubated 
for another 24 hours. Forty-eight hours after transfection, the supernatant of each plate was 
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collected and centrifuged at 2000 rpm for five min to remove cell debris. The supernatant was 
then separated into 1 mL aliquots and stored in -80°C for further use. See Table 2 for list of 
viruses of interest in this study.  
 
Table 2. Viruses of Interest 
Virus Targeted Receptor 
NL43  CXCR4 
NL43 + VSV-G Env NA 
NLYU25A (brain isolate) CCR5 
NLYU25A + VSV-G Env NA 
NLAD8 (Macrophage Isolate) CCR5 
NLAD8 + VSV-G Env NA 
3.8 QUANTIFYING VIRUS TITER  
Virus titer was calculated by using a TZM-bl assay using the supernatants of the transfected 
293T cells. 8.0 X 103 TZM-bl cells were plated in triplicate within a 96 well flat bottom plate for 
24 hours. Upon reaching over 80% confluency, the cells were infected with various 
concentrations of virus: 1:10, 1:100, and finally, 1:1000. After 48 hours, the cells were observed 
under fluorescent microscope. In order to calculate the virus titer, the number of green cells was 
counted in the wells containing the 1:1000 dilution. The average of the triplicate was calculated 
and the resulting value was multiplied by 1,000 to obtain the number of infectious particles per 
μL of media.  
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3.9 INFECTION OF NORMAL HUMAN ASTROCYTES   
In order to transfect normal human astrocytes, 50,000 astrocyte cells were plated in a 24-well 
culture plate, with 200 μL of astrocyte media, and incubated for 24 hours. Once reaching over 
85% confluency, the cells were infected with 1 MOI and 0.1 MOI concentrations of the 
respective virus. The cells were then incubated. Twenty-four hours post-transfection, the existing 
astrocyte media was removed, the cells were washed with excess PBS solution, and 200 μL of 
fresh astrocyte media was added to the wells. Forty-eight hours post transfection, the cells were 
then observed under fluorescent microscope for evidence of green fluorescence. While the 
number of green cells were not counted, the appearance of green fluorescence was noted for each 
virus.  
3.10 INFECTION OF MIRNA TRANSDUCED ASTROCYTES  
A similar procedure as stated above was performed in order to infect the miRNA expressing 
astrocytes. However, since these cells already express green fluorescence due to EGFP present in 
the miRNA vector, the infectivity of the virus was not determined via observation of green 
fluorescence under the microscope. In order to determine the infectivity of the virus, the 
supernatant was taken from these cells 48 hours post-transfection and added to plated TZM-bl 
cells in a 96-well flat bottom culture plate (procedure below).  
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3.11 INFECTION OF TZM-BL CELLS WITH SUPERNATANT FROM INFECTED 
ASTROCYTES 
In order to test the infectivity of the viral proteins produced by the infected normal and miRNA 
astrocytes, the supernatant from these cells was added to TZM-bl cells. First, 8,000 TZM-bl cells 
were plated in a 96-well flat bottom plate with 100 μL of D10 media and incubated overnight 
until greater than 80% confluency was reached. Viral supernatant, in varying concentrations (100 
μL and 10 μL), was added directly to the TZM-bl assay. The cells were then incubated for 48 
hours. After 48 hours, the cells were observed under fluorescent microscope for evidence of 
green fluorescence.  
3.12 BETA GALACTOSIDASE ENZYME ASSAY TO TEST THE INFECTIVITY OF 
VIRUS PRODUCED BY THE INFECTED MIRNA EXPRESSING ASTROCYTES 
Seventy- two hours post infection, supernatant from the miRNA expressing astrocytes were 
collected and the infectivity of the virus released in the supernatant was measured using TZM-bl 
assay and β- Galactosidase assay as described by the manufacturer protocol. Briefly, 
supernatants were incubated with the TZM-bl cells in a 96-well plate for forty-eight hours. At 
this point, the cells were washed and lysed in 50 μL of lysis buffer. After five minutes of lysis on 
ice, 50 μL of Beta-Glo® reagent (Promega, Madison, WI) was added to the TZM-bl cell 
monolayers, and the reaction mixture was transferred to a black 96-well plate and 
chemiluminescence activity was read using a luminometer.  
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4.0  RESULTS  
4.1 GENERATE ASTROCYTE CELLS EXPRESSING CANDIDATE MIRNA 
4.1.1 Verification of transduction via fluorescent microscopy  
Fluorescent microscopy was used to verify the successful transduction of the miRNA expression 
vector in the normal human astrocyte cell line. Since the expression vector contained Enhanced 
Green Fluorescent Protein (EGFP), the cells were observed under green fluorescence light under 
the microscope. Evidence of green fluorescence indicates successful transduction of all four 





Figure 2. Fluorescent Microscope Images of miRNA transduced astrocytes 
MicroRNA transduced astrocytes were grown on a cover slip and fixed with 2% paraformaldehyde. 
Coverslip was viewed under the fluorescence microscope and images were captured at 40X 
magnification.  
A. Scramble  B. miR-let-7a C. miR- 20a 
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4.1.2 Verification of Transduction via Flow Cytometry  
Further analysis was performed via flow cytometry to see if the miRNA were transduced into the 
normal human astrocyte cells. The results from the flow cytometry show that more than 90% of 
cells are EGFP+, indicating successful transduction of the candidate miRNA (Figure 3).  
 
Figure 3. Flow Cytometry Results of miRNA Expressing Astrocytes.  
MicroRNA transduced astrocytes were grown and fixed with 2% paraformaldehyde and measured 
by flow cytometry. The untransduced astrocytes show 20% green fluorescence. Scramble expressing 
astrocytes show 90% green fluorescence.  The astrocytes expressing miR-let-7a and miR-20a are 
96% and 94% EGFP+, respectively.  
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4.1.3 Total RNA Extraction  
RNA extraction was done in order to prepare for Real Time PCR to verify the transduction of the 
miRNA into the astrocyte cell line. Results are summarized in Table 3. Nucleic acid 
concentrations were low in all four miRNA types, and therefore Real Time PCR was not 
performed.  
 
Table 3. RNA Extraction Results 
miRNA NA (ng/μL) A260/A280 
miR-20a 63.5 2.11 
miR-106b 48.0 2.05 
miR-let-7a 30.3 1.84 
miR-Scr 42.4 2.09 
4.2 INFECTION OF NORMAL AND MIRNA EXPRESSING ASTROCYTES  
4.2.1 293T Infectivity Assay  
Table 4 shows the results of the infectivity assay conducted for all six viruses of interest for this 
study. The data are given as the number of infectious particles per mL. The viruses made with 
VSV-G had the highest titer, with NLAD8 with VSV-G having the highest titer of all six viruses. 
NLYU25A and NLYU25A + VSV-G had the next highest titer. Finally, the NLAD8, NL43 + 
VSV-G, and NL43 showed the lowest titer. This information was used to plan the next steps of 
the experiments, specifically when determining the amount of each virus that is needed to infect 
the normal human astrocytes and miRNA expressing astrocytes.  
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Table 4. Estimation of virus titer using TZM-bl cells 
Virus Titer (Infectious particles/ mL) 
NL43 0.70 x 105 
NL43 + VSV-G 0.98 x 105 
NLYU25A 0.10 x 106 
NLYU25A + VSV-G 1.5 x 105 
NLAD8 0.80 x 105 
NLAD8 + VSV-G 8.1 x 105 
 
4.2.2 Verification of Infection of Normal Human Astrocytes via Fluorescent Microscope  
Fluorescent microscopy was used to determine if the virus was successful in infecting the normal 
human astrocytes. The astrocytes plate was read 48 hours post transfection. Results are 
summarized below in Table 5. The experiment was repeated three times in order to gain a 
consensus on the ability of each virus to infect the astrocytes.  
All viruses, in both concentrations, that utilized the VSV-G envelope protein were able to 
successfully infect the normal human astrocytes, as observed under the fluorescent microscope. 
Additionally, the NL43 virus consistently was able to infect the astrocytes, in both 
concentrations of virus tested. The NLYU25A virus was not able to infect the astrocytes. 
NLAD8 showed inconsistent results, however from the last two experiments, the virus was not 
able to infect. Finally, the YU2 and AD8 viruses, used as positive controls, were not able to 




Table 5. Transfection of Normal Human Astrocytes: Evidence of Green Fluorescence as Observed 
under Microscope 
 
Results of Infection of Normal Human Astrocytes 
 Experiment 1 Experiment 2 Experiment 3 
Virus of Interest 50 μL 5 μL 1 MOI 0.1 MOI 1 MOI 0.1 MOI 
NL43 + + + + + + 
NL43 + VSV-G + + + + + + 
NLYU25A − − − − − − 
NLYU25A + VSV-G − + + + + + 
NLAD8 + + − − − − 
NLAD8 + VSV-G + + + + + + 
       
       
Results of Infection of Normal Human Astrocytes- Positive Control 
 Experiment 1 Experiment 2 Experiment 3 
Virus of Interest 50 μL 5 μL 1 MOI 0.1 MOI 1 MOI 0.1 MOI 
YU2 NI NI − − − − 
YU2 + VSV-G NI NI + + + + 
AD8 NI NI NI NI − − 
AD8 + VSV-G NI NI NI NI + + 
       
 Table Legend     
 + Green     
 − No Green     
 NI Not Included      
4.2.3 Verification of Infection of miRNA Expressing Astrocytes via TZM-bl Infectivity 
Assay 
Since the miRNA expressing astrocytes already express green fluorescence due to the presence 
of EGFP within the vector, fluorescent microscopy was not used to determine whether these 
astrocytes were infected with the viruses of interest. Instead, in order to further determine the 
infectivity of the miRNA expressing astrocyte supernatant, β-Galactosidase assays were 
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performed on the infected TZM-bl cells to measure chemiluminescence activity. Forty- eight 
hours post transfection, the cells were first lysed with lysis buffer for five minutes, after which 
50 μL of Beta-Glo® reagent was added to the cells to measure chemiluminescence activity. 
Results are summarized in the figure below (Figure 4). Figure 4A suggests that miR-20a and 
miR-141 did not significantly increase NL43 infectivity (p > 0.05). miR-106b significantly 
increases NL43 infectivity (p < 0.05). Figure 4B suggests that mi-R20a did not significantly 
decrease virus infectivity of NL43 + VSVG (p > 0.05), and miR-106b and miR-let-7a did not 
significantly increase infectivity (p > 0.05). Furthermore, figure 4C shows that miR-20a, miR-
106b, miR-let-7a did not significantly increase virus infectivity of NLYU2 (p > 0.05). Figure 4D 
suggests that mi-R20a and miR-106b did not significantly decrease virus infectivity of NLYU2 + 
VSVG (p > 0.05), and miR-let-7a did not significantly increase infectivity (p > 0.05). Figure 4E 
shows that mi-R20a did not significantly decrease virus infectivity of NLAD8 (p > 0.05), and 
miR106b and miR-let-7a did not significantly increase infectivity (p > 0.05). Finally, Figure 4F 
suggests that miR-20a, miR-106b and miR-let-7a did not significantly increase virus infectivity 
of NLYU2 + VSVG (p > 0.05). Due to the relatively small sample sizes used in these 










Figure 4. β-Gal Assay to Quantify Virus Infectivity in TZM-bl cells 
β-Galactosidase assays were performed on the infected TZM-cells. Forty-eight hours post transfection, the cells 
were lysed with lysis buffer for five minutes, after which 50 μL of Beta-Glo® reagent was added to the cells and 
chemiluminescence activity was measured. The assay was done twice. A. miR-20a and miR-141 did not 
significantly increase NL43 infectivity (p > 0.05). miR-106b significantly increases NL43 infectivity (p < 0.05). B. 
mi-R20a did not significantly decrease virus infectivity of NL43 + VSVG (p > 0.05), and miR-106b and miR-let-7a 
did not significantly increase infectivity (p > 0.05). C. miR-20a, miR-106b, miR-let-7a did not significantly increase 
virus infectivity of NLYU2 (p > 0.05). D. mi-R20a and miR-106b did not significantly decrease virus infectivity of 
NLYU2 + VSVG (p > 0.05), and miR-let-7a did not significantly increase infectivity (p > 0.05). E. mi-R20a did not 
significantly decrease virus infectivity of NLAD8 (p > 0.05), and miR106b and miR-let-7a did not significantly 
increase infectivity (p > 0.05). F. miR-20a, miR-106b and miR-let-7a did not significantly increase virus infectivity 

































































5.0  CONCLUSION  
The study’s first aim was to generate an astrocyte cell line that expresses the selected candidate 
miRNA. This was successfully accomplished through the use of a miRNA lentivirus expression 
vector that expresses the Enhanced Green Fluorescence Protein. Through the use of microscopy 
and flow cytometry, the transduction was shown to be successful, as both procedures produced 
evidence of green fluorescence. While the initial plan was to perform Real Time PCR on these 
cells to further confirm the transduction, PCR was not conducted due to low concentration of 
RNA in all four miRNA expressing astrocytes.  
 The second aim of this study was to investigate whether the overexpression of the 
candidate miRNA within astrocytes blocks viral replication. The results from this study first 
show that HIV-1 is able to infect normal human astrocytes. In particular, NL43 and 
NL43+VSVG are able to infect. However, NLYU2 and NLAD8 are not able to infect these 
astrocytes, but are able to infect when trans-complemented with VSV-G Envelope.  
 Furthermore, the results from this study show that host factors, specifically miRNA, have 
the potential to play a role in the replication of HIV-1 within astrocytes. From the β-Gal assay, 
there appears to be some affect of the candidate miRNA on virus infectivity within TZM-bl cells. 
The NL43 virus infectivity was shown to increase in all three cases of miRNA. This increase was 
significant in the astrocytes expressing miR-106b (p < 0.05). However, miR-20a appears to 
decrease infectivity of NL43 + VSVG, NLYU2 + VSVG, and NLAD8.  miR-106b appears to 
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have mixed affects on each individual virus, with no significant differences in any. Finally, miR-
let-7a appears to increase the infectivity of all six viruses used in the study.  
While these results represent a preliminary investigation into the role of miRNA in virus 
replication within astrocytes, more research should be done to further elucidate the mechanism(s) 
of action of these miRNAs. The findings of this study add to existing literature by demonstrating 
a relationship between miRNA expression and virus infectivity of HIV-1 within astrocytes. The 
role of miRNA in virus replication is an area of HIV-1 research that should studied in greater 
detail, in order to potentially create a therapeutic to combat HIV-1 replication within astrocytes 




6.0  DISCUSSION  
Since 1996, with the availability of combination antiretroviral therapy (cART), the morbidity and 
mortality rates of HIV-1 infection have decreased significantly, and the life expectancies of those 
who receive treatment have increased [39]. Along with these improvements, the incidence of 
HIV-associated Dementia, the most severe neurological disorder associated with HIV-1 
infection, has also decreased. However, neurological complications associated with HIV-1 
infection still persist in milder forms, which are collectively known as HIV-associated 
neurocognitive disorder (HAND) [39-40]. Despite the success of cART in treating infection and 
improving the immune function of those infected, more attention needs to be devoted to 
understanding the comorbidities associated with HIV-1 infection within the CNS, in order to 
improve both diagnosis and treatment plans. HAND affects between 30-70% of all HIV-1+ 
patients, and even those patients who have an undetectable viral load due to effective treatment 
with cART experience neurological dysfunctions due to HIV-1 infection [40-42]. This indicates 
that there needs to be a greater focus in studying and developing a therapeutic for the 
neurological symptoms associated with HIV-1 infection, especially since HIV-1 positive patients 
are living longer lifespans.  
The results of this study provide support for the need of further research into the 
neuropathogenesis of HIV-1 within the CNS. By demonstrating an affect of candidate miRNA 
on the infectivity of the viruses studied in this project, it is clear that these miRNA do in fact play 
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a role in the virus replication process within astrocytes. More research is needed to elucidate the 
mechanism of action of these miRNAs in order to determine whether they specifically play a 
helpful or harmful role within the pathogenesis of HIV-1 within the brain. The affect of miRNA 
on virus infectivity and replication suggests the potential for these candidate miRNA to serve as 
therapeutics to combat the neurocognitive symptoms that occur over time in HIV-1 positive 
individuals.  
6.1.1 Limitations  
While the results of this study offer preliminary insights into the role of candidate miRNA in the 
pathogenesis of HIV-1 within the CNS, the experiments need to be repeated to test for 
consistency and confirm the relation between the miRNA and virus infectivity. In order to 
confirm the successful transduction of the candidate miRNA, real time RNA PCR must be 
conducted. Since the nucleic acid concentration was found to be too low during RNA extraction, 
PCR was not conducted. This experiment should be repeated using a greater number of miRNA 
transduced astrocytes, in order to successfully carry out the PCR and confirm the transduction.  
Furthermore, the virus titers of all six viruses used in this project were fairly low, which 
could affect the levels of infectivity seen within both the normal and miRNA expressing 
astrocytes. In future studies, viruses with a greater titer should be used in order to increase the 
efficiency of the virus infection and obtain more consistent results. Additionally, the VSV-G 
envelope protein was used to increase infection efficiency within the experiments. However, this 
method of infection is artificial and does not represent the way the HIV-1 virus enters a host cell 
in nature. Future studies should take this into consideration and could perhaps use more natural 
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methods of viral entry, as this may affect the ability of the miRNA to regulate the viral 
replication and infectivity of HIV-1.  
6.1.2 Future Directions  
The results of this study lend themselves to further research that will be useful in determining the 
specific role of miRNA in the neuropathogenesis of HIV-1 within the CNS. This study focused 
on the infection and viral replication of HIV-1 within astrocytes. However, since astrocytes have 
inflammatory properties, the role of miRNA in regulating neuroinflammation can be a future 
study that stems from this project. Previous studies have shown that astrocytes become activated 
and inflammatory in the presence of neuronal injury [18-33]. These activated astrocytes, known 
as A1 astrocytes, then release toxic factors that can cause cell dysfunction and death of 
surrounding neurons, which can then contribute to the pathogenesis of neurocognitive disorders 
within the brain [43]. Furthermore, A2 astrocytes, which are another type of activated astrocyte, 
have been shown to have neuroprotective properties in the presence of neuronal injury [44]. The 
affect of miRNA on viral replication of these specific astrocyte types could further elucidate the 
mechanism of action of these miRNA in the neuropathogenesis of HIV-1 within the CNS.  
In addition, there have been several hypotheses for other modes of HIV-1 infection 
within astrocytes. One of these hypotheses proposes that astrocytes become infected through the 
cell-to-cell transfer of HIV-1 virus from macrophages to astrocytes. Astrocytes have also been 
shown to have endocytotic properties, which could be another way the virus enters these cells 
[45-47]. In future, studies, co-culturing infected macrophages with astrocytes could be another 
way to induce infection within these cells and study the role of miRNA in the viral replication of 
virus that is obtained in this way.  
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The questions explored in this project can contribute to the existing scientific knowledge 
regarding the role of host factors on the pathogenesis of HIV-1 within the central nervous 
system. This research combined with research in the areas mentioned above can significantly 
help in the development of more specific therapeutics in treating HIV-1 CNS infection and 
HAND. Since the prevalence of HAND is increasing, research investigating HAND pathogenesis 
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